Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMRN with free AI briefings, catalyst countdowns, and dilution alerts.

IMRN · Immuron Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9M Cash on Hand
33.2mo Cash Runway
Follow IMRN by email Get an email when IMRN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMRN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
IMM 124-E Nonalcoholic Steatohepatitis Phase 2 · NCT01466894 Withdrawn
IMM-124E Nonalcoholic Fatty Liver Disease (NAFLD) Phase 2 · NCT03042767 Completed
IMM-529 Clostridium Difficile Infection Phase 1/2 · NCT03065374 Terminated
Travelan Diarrhea Phase 2 · NCT05933525 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMRN holds $9M in cash and short-term investments and burns about $814,930/quarter from operations, an estimated runway of 33.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 14 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMRN files for a raise →

👥 Who Owns IMRN

Insiders 1.9% Institutions (6 holders) 2% Public and other holders 96.1%
HolderTypeShares% of sharesAs of
Steven George Lydeamore
Chief Executive Officer
Insider 3,155,047 0.98% 2026-03-18
Flavio Palumbo
Chief Commercial Officer
Insider 1,142,909 0.35% 2026-03-18
Ravi Savarirayan
Director
Insider 877,840 0.27% 2026-03-18
Daniel Jude Pollock
Director
Insider 743,230 0.23% 2026-03-18
Jerry Kanellos
Chief Scientific Officer
Insider 333,000 0.10% 2026-03-18

Share count 322,848,081 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMRN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMRN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.